

Princess Private Equity Holding Limited
0% Coupon Principal protected AA+ Convertible Bond due 2010

Key Figures

	March 31, 2003	February 28, 2003
Net Asset Value (NAV)	78.21%	78.12%
Mid Market Price	71.50%	71.50%
Premium over NAV	-8.58%	-8.47%
Net Liquidity	USD 36,937,675	USD 46,636,114
Value of PE Investments	USD 511,307,147	USD 500,974,895
Undrawn Commitments	USD 400,424,532	USD 410,592,775
Investment Level	93.26%	91.48%
Overcommitment	66.30%	66.46%

**Value of PE Investments by Geographic Region
and Financing Stage**




■ N/America 51% ■ W/Euro 45% ■ RoW 4%



■ Buyout 55% ■ Venture 28% ■ Special Situations 17%

Value of PE Investments by Industry



Preliminary findings of the '2003 Pan-European Investment Benchmark Study' carried out by Thomson Venture Economics and the European Private Equity and Venture Capital Association (EVCA) show that the long-term performance of private equity has remained solid. Results for European private equity returns from end-1979 to end-2002 reveal a performance (IRR) of 11.5% p.a. This compares favorably to average annual returns of 7.6% for the DAX (the only European index that covers this time period). Furthermore, short-term private equity returns, (measured using one and three-year horizon IRRs) of -8.2% and 4.1% respectively are also considerably higher than annualized average returns for the MSCI Europe (-30.9% and -18.2% respectively) for the same time periods. Recent transactions involving private equity partnerships in which Princess is invested include Cinven's sale of Odeon Cinemas to a syndicate of investors led by WestLB for GBP 431m – this transaction underlines the prevailing trend of secondary buyouts to provide private equity firms with liquidity. The Rutland Fund's acquisition of the musical instrument division of Boosey & Hawkes PLC, which comprises some of the world's leading instrument and accessory brands. In addition, the Heidelberg-based pharmaceutical company Cellzome, a Sofinnova Partners portfolio company, announced the completion of a Series C funding at a total of approx. EUR 30m.

The accompanying notes form an integral part of this newsletter

Monthly Newsletter As of March 31, 2003



Definitions

This Newsletter is produced based on information available on the last working day of the month.

The NAV (Net Asset Value) is calculated based on a total of 7,010,000 fully diluted shares. Princess has 10,000 issued shares and 700,000 convertible bonds that, if converted at USD 100 per share, would result in 7,000,000 shares giving an overall total of 7,010,000 shares.

Mid Market Price	The arithmetic mean of bid and offer closing prices on the last trading day of the month as reported to Princess
NAV	Gross consolidated assets less consolidated liabilities, save that the principal amount of the bonds shall be treated as equity (For further details please refer to the Bond's Offering Circular dated 30.09.99, page 43)
Premium Over NAV	Mid Market Price divided by NAV
Net Liquidity	Current assets less liabilities due within one year (undrawn commitments not taken into consideration)
Value of PE Investments	Fair value of private equity (limited partnership) investments and directly held investments as of the last valuation date of fund vehicles adjusted for subsequent activity
Undrawn Commitments	Sum of all open and not drawn obligations to fund PE Investments
Investment Level	Value of PE Investments divided by NAV
Overcommitment	Undrawn Commitments less Net Liquidity divided by NAV

Regions

N/Am	North America
W/Euro	European Union & European Free Trade Association
RoW	Rest of World

Financing Stages

Venture Capital (VC)	A vehicle which is engaged in an investment strategy involving financing portfolio companies for product development and initial marketing, manufacturing and sales activities. Seed Stage of investing involves product viability risk, whereas Early Stage involves defining competitive market arenas and developing production and marketing channels. Later Stage investing involves portfolio companies for rapid expansion. Risk at this stage revolves around capturing market share while increasing production and delivery capabilities and building sales volumes.
Buyout (BO)	A vehicle which is engaged in the purchase of securities of a company, resulting in the vehicle attaining at least a controlling percentage of such company's securities and thereby exercising control over its assets and operations. Small / Mid Size Buyouts are defined as vehicles which are engaged in the purchase of securities of a company with capitalization under USD 1 billion. Large Size Buyouts are defined as vehicles which are engaged in an investment strategy involving financing portfolio companies with capitalization in excess of USD 1 billion for rapid expansion. The risk at this stage involves capturing market share while increasing production and delivery capabilities and building sales volumes.
Special Situations (SS)	Any investment which falls within the definition of private equity but which does not fall within the above definitions of Venture Capital and Buyout. Special Situation investments include, among others, mezzanine investments and investments in "distressed" enterprises.

Investor Relations
Partners Group
Dr. Claudia Petersen
Zugerstr. 57
6341 Baar-Zug
Switzerland

Phone: +41 (0)41 768 8551
Facsimile: +41 (0)41 768 8557
Mail: claudia.petersen@partnersgroup.net

Princess Private Equity Holding Limited
P.O. Box 477
St. Peter Port
Guernsey, GY1 6BD
Channel Islands

Phone: +44 (0) 1481 730 946
Facsimile: +44 (0) 1481 730 947
Mail: princess@princess-privateequity.net
www.princess-privateequity.net


German Security Number: 313.965
Swiss Security Number: 813.917
ISIN Code: XS0098576563

Reuters: DBSTRUOK03
Bloomberg: PRINEQ <<corp>> RELS <go>
Telekurs: CH813917

This monthly newsletter was prepared using financial information contained in the company's books and records as of March 31, 2003. This information is believed to be accurate but has not been audited by any third party and no independent accounting firm has expressed an opinion such as information or financial statements. This document is not intended to be an investment advertisement; it constitutes neither an offer nor an attempt to solicit offers for regulated investments. The company does not accept liability for the results of any action taken on the basis of the information provided or for any other errors or omissions contained therein.

Princess Private Equity Holding Limited
0% Coupon kapitalgeschützte AA+ Wandelanleihe fällig 2010

Kennzahlen	31. März 2003	28. Februar 2003
Innerer Wert (NAV)	78.21%	78.12%
Mittelkurs	71.50%	71.50%
Prämie über NAV	-8.58%	-8.47%
Netto Liquidität	USD 36,937,675	USD 46,636,114
Wert der PE Investitionen	USD 511,307,147	USD 500,974,895
Nicht abgerufene Zahlungsversprechen	USD 400,424,532	USD 410,592,775
Investitionsgrad	93.26%	91.48%
Overcommitment	66.30%	66.46%



Die vorläufigen Resultate der *2003 Pan-European Investment Benchmark Study*, die im Auftrag von Thomson Venture Economics und der European Private Equity and Venture Capital Association (EVCA) ausgeführt wurde, zeigen, dass die Langzeit-Performance von Private Equity stabil ist. Die europäischen Private Equity-Renditen zwischen Ende 1979 und Ende 2002 weisen eine Performance (IRR) von 11.5% p.a. auf und schneiden somit im Vergleich zur durchschnittlichen Rendite des DAX (des einzigen europäischen Indexes, der diese Zeitspanne abdeckt), die 7.6% p.a. betrug, besser ab. Außerdem ergeben die kurzfristigen Renditeberechnungen (Ein- und Dreijahres-IRRs) eine Performance von -8.2% und 4.1%, was immer noch markant höher ist als die annualisierten Durchschnittsrenditen des MSCI Europe (-30.9% und -18.2%) für dieselbe Zeitperiode. Zu den jüngsten Transaktionen von Partnerships, an denen Princess beteiligt ist, gehören unter anderem Cinvens Verkauf von Odeon Cinemas für GBP 431 Mio. an ein durch WestLB angeführtes Syndikat von Investoren. Diese Transaktion unterstreicht den anhaltenden Trend von Sekundär-Buyouts an Private Equity-Unternehmen, die mit ausreichender Liquidität ausgestattet sind. Des Weiteren ist die Akquisition der Musikinstrumente-Sparte von Boosey & Hawkes PLC, die einige der weltweit führenden Instrumente- und Zubehör-Marken umfasst, durch The Rutland Fund zu erwähnen. Das in Heidelberg ansässige Pharmaunternehmen Cellzome, ein Portfolio-Unternehmen von Sofinnova Partners, konnte außerdem den Abschluss ihrer Anschlussfinanzierung von insgesamt ca. EUR 30 Mio. bekannt geben.

